Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials

The cancer operation for gallbladder cancer: the gallbladder (if still present) is removed together with a rim of the liver it sits against and the lymph nodes along the bile duct and liver blood vessels. After an incidental cancer it is done as a second operation about four to eight weeks after the first.

Incidental gallbladder cancer is cancer the pathologist finds in a gallbladder removed for gallstones or inflammation, when nobody suspected it. It is the commonest way this cancer is found early enough to cure. Whether a second operation is needed depends on how deep the tumour went: none for the earliest layers, a radical operation at a specialist centre for T1b or deeper.

Removing or destroying tumours physically, increasingly with robots, image guidance, and heat or cold instead of a knife.

Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it.

The 1976 paper that first staged gallbladder cancer by how deeply it had grown through the wall, noting that almost every case had been found by chance during gallstone surgery.

Where a muscle-invading gallbladder tumour sits matters: those on the side against the liver spread more and killed more, with five-year survival of 43 in 100 against 65 in 100 for tumours on the free side.

The editorial announcing the 2017 staging changes for pancreas, liver and biliary cancers, including the split of muscle-invading gallbladder cancer into a free-side and a liver-side category.

Tested on 7,743 US patients, the 2017 gallbladder cancer staging system predicted survival no better than the 2010 one it replaced.

Since 2017 a gallbladder tumour that has reached the muscle layer is split by which side of the gallbladder it sits on: the free side facing the abdomen (T2a) does better than the side stuck to the liver (T2b).

TNM staging is the universal system describing tumour size (T), lymph node spread (N), and distant metastasis (M).

When surgeons went back in after a gallbladder cancer had been found by chance, nearly half of patients had cancer left behind, and the deeper the original tumour the more likely it was.

Across ten US centres, people whose second operation for a chance-found gallbladder cancer happened four to eight weeks after the first lived longest; rushing back in under four weeks, or waiting beyond eight, went with shorter survival.

Pooling individual records from more than 2,000 patients, the timing of the second operation for chance-found gallbladder cancer made no measurable difference to survival, and studies did not even agree on what early or late meant.

In the Dutch national registry only one in four people with a chance-found gallbladder cancer had the recommended second operation; those who did lived about four times longer, and a third of them had cancer left behind that the operation removed.

The first UK-wide picture of gallbladder cancers found by chance: across 24 centres over nine years, two thirds went on to liver surgery and those who did stayed free of disease far longer.

Across 14 specialist centres in Korea, Japan, Chile and the United States, people with a gallbladder cancer that had just reached the muscle layer did equally well whether or not they had a second, bigger operation: about 95 in 100 were alive and free of the disease at five years either way.

Pooling seven studies, muscle-invading gallbladder cancers on the liver side were about twice as likely to be fatal as those on the free side, yet the bigger operation did not clearly improve survival in either group.

A British Journal of Surgery review of what to do when a gallbladder removed for stones turns out to hold cancer: about one in 200 do, tumours confined to the lining are cured by the first operation, deeper ones need a second, and cutting out the keyhole port sites does not help.

Incidental gallbladder cancer is cancer the pathologist finds in a gallbladder removed for gallstones or inflammation, when nobody suspected it. It is the commonest way this cancer is found early enough to cure. Whether a second operation is needed depends on how deep the tumour went: none for the earliest layers, a radical operation at a specialist centre for T1b or deeper.

The cancer operation for gallbladder cancer: the gallbladder (if still present) is removed together with a rim of the liver it sits against and the lymph nodes along the bile duct and liver blood vessels. After an incidental cancer it is done as a second operation about four to eight weeks after the first.

About six in every thousand gallbladders removed for stones contain cancer. A written pathway that sends every specimen to the pathologist, refers every T1b or deeper cancer to a liver surgeon within two weeks and books the second operation within eight would turn a lottery into a system.

Guidelines send everyone whose chance-found gallbladder cancer has just reached the muscle layer back for liver and lymph node surgery, yet the largest international series found 95 in 100 alive without the disease at five years whether or not they had it. A prospective study could spare thousands of operations, or confirm they are needed.

Muscle-invading gallbladder tumours on the free side of the organ recur in the liver far less often than those against it. Two meta-analyses found the liver resection helped only the liver-side group, so a randomised trial could test dropping it for the free side.

ABC-02 was the 2010 UK trial that gave bile duct cancer its first standard chemotherapy: 410 patients with advanced biliary tract cancer were randomised to gemcitabine plus cisplatin or gemcitabine alone, and the doublet lengthened life and delayed progression. It stayed the control arm for every first-line trial for more than a decade.

Adding cisplatin to gemcitabine lengthened survival by more than three months in advanced bile duct and gallbladder cancer without extra serious toxicity, establishing the chemotherapy standard for the disease.

Gemcitabine plus cisplatin has been the chemotherapy backbone for bile duct cancer since 2010 and is now given with immunotherapy.

Cancer Research UK is the world's largest independent cancer research charity, funding the Crick, ICR, Manchester, Cambridge, and the STAMPEDE and TRACERx trials.

Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1.

Drugs that kill fast-dividing cells. Still the backbone of many cures, and now the warhead inside smarter drugs.

Six months of oral chemotherapy after surgery became the standard for bile duct cancer despite a technically negative primary result.

Six months of capecitabine tablets after surgery for bile duct or gallbladder cancer lengthened survival by about a year in the per-protocol analysis, and became the standard adjuvant treatment despite narrowly missing its primary endpoint.

ABC-06 was the first randomised trial to show that a second round of chemotherapy, FOLFOX, helps people with bile duct and gallbladder cancer live somewhat longer once gemcitabine and cisplatin have stopped working.

The UK trial that showed a second chemotherapy, FOLFOX, helps people with advanced bile duct or gallbladder cancer live about a month longer on average once gemcitabine and cisplatin stop working, with one in four alive at a year instead of one in nine.

A Korean randomised trial in which adding liposomal irinotecan to fluorouracil lengthened the time before second-line bile duct and gallbladder cancer grew; a later German trial did not reproduce the gain.

In a Korean trial, adding liposomal irinotecan to fluorouracil held second-line bile duct and gallbladder cancer still for about seven months rather than six weeks, at the cost of more low blood counts.

Adding a liposomal chemotherapy did not help in second-line bile duct cancer, contradicting an earlier Korean trial.

Among 516 people operated on for gallbladder cancer at 24 UK centres, how far the tumour had grown and whether nodes were involved decided survival, and chemotherapy after surgery showed no measurable benefit once like was compared with like.

Capecitabine (Xeloda) is a tablet form of the chemotherapy fluorouracil. It is a backbone of treatment for bowel cancer and a standard option in advanced breast cancer.

FOLFOX is the workhorse chemotherapy combination for bowel cancer, used after surgery to cure and in advanced disease as the backbone that targeted drugs are added to.

British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer.

Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer.

The Christie is Europe's largest single-site cancer centre and the UK's first NHS proton therapy centre.

The only prospective trial of chemotherapy followed by radiotherapy after gallbladder or bile duct surgery: two in three patients were alive at two years, even when the margin had been involved, but with no comparison group the benefit is unproven.

In the only prospective trial of chemotherapy then radiotherapy after surgery for gallbladder or bile duct cancer, two in three patients were alive at two years, including those whose cancer had reached the cut edge, but there was no comparison group.

Using US Medicare records from 1,137 older patients, a calculator was built to estimate who might gain from radiotherapy with chemotherapy after gallbladder cancer surgery; it points to those whose tumour had reached the muscle layer or the nodes.

An Indian randomised trial asking whether adding radiotherapy to chemotherapy before surgery shrinks locally advanced gallbladder cancer enough to help people live longer.

Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation. It is the curative treatment for cervical, anal, laryngeal and oropharyngeal cancers, stage III lung cancer and glioblastoma, and is given before surgery in oesophageal and rectal cancer, at the cost of more acute mouth and gullet inflammation.

Using high-energy X-rays or particles to damage the DNA of cancer cells in a precisely aimed volume of the body. On its own it cures early prostate, larynx, cervix and skin cancers, it is combined with chemotherapy in head and neck, lung, oesophageal and rectal cancers, and about half of all cancer patients receive it.

SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.

Radiotherapy after gallbladder cancer surgery rests on one 79-patient trial with no comparison arm and a US insurance database. People whose surgery left cancer at the edge or in the nodes are the ones it might help, and they have never been randomised.

TOPAZ-1 was the first immunotherapy success in bile duct cancer, with a small median gain but a growing tail of long survivors.

Adding durvalumab to gemcitabine-cisplatin lengthened survival in advanced bile duct and gallbladder cancer, the first improvement on chemotherapy alone in more than a decade, with about a quarter of patients alive at two years.

Three and a half years on, adding durvalumab to chemotherapy for advanced bile duct and gallbladder cancer still showed a survival edge, and about one in seven patients were alive at three years compared with one in fourteen on chemotherapy alone.

A second immunotherapy trial confirmed the modest survival benefit of adding PD-1 blockade to chemotherapy in bile duct cancer.

Adding pembrolizumab to gemcitabine-cisplatin, with gemcitabine continued as maintenance, lengthened survival in advanced biliary tract cancer by about two months, confirming the role of chemo-immunotherapy shown by TOPAZ-1.

Chemotherapy plus immunotherapy is now the first treatment for advanced bile duct cancer, with a small average gain and a minority of long survivors.

A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.

Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.

Gallbladder tumours from the United States and Chile carried the same set of mutated genes but very different immune cell make-up, which may bear on why immunotherapy helps only modestly and on how trials should be designed across regions.

Immune checkpoint inhibitors are antibodies against CTLA-4, PD-1 or PD-L1 that release the brakes on T cells so they attack the cancer. They are approved in more than 20 tumour types and produce lasting, sometimes curative responses that chemotherapy rarely does, but most patients do not respond and autoimmune side effects are the cost.

Immunotherapy helps the patient's own immune system recognise and destroy the cancer.

Every drug gallbladder cancer patients receive was tested in mixed bile duct trials where they were a subgroup. Requiring trials to pre-specify and publish gallbladder results, with a minimum number enrolled, would give the disease its own evidence at almost no cost.

Pooling 40 studies, about one in five bile duct and gallbladder cancers outside the liver over-express HER2, against fewer than one in twenty inside the liver, which is why HER2 drugs matter most for gallbladder cancer.

In 140 resected bile duct and gallbladder cancers tested the way the zanidatamab trial did, about one in eleven was HER2-positive, and the HER2 signal was often patchy, present in under half the tumour cells.

The single-arm trial that won zanidatamab its approval: about four in ten patients with HER2-positive bile duct or gallbladder cancer responded after chemotherapy had failed.

Paper cited by one cancer page, indexed on Europe PMC as PubMed record 37276871 and published in The Lancet Oncology; the citing page links this DOI, which is how the record was matched.

Tests whether the HER2 bispecific antibody should be given from the start in HER2-positive bile duct cancer.

DESTINY-PanTumor02 gave the HER2-directed antibody-drug conjugate Enhertu to 267 patients in seven cohorts of HER2-expressing solid tumours, endometrial and cervical cancer among them. Endometrial cancer responded best, and in April 2024 the FDA granted the first tumour-agnostic HER2 approval, for tumours with the strongest HER2 staining and no satisfactory alternative.

Across seven tumour types including endometrial, cervical and ovarian cancers, trastuzumab deruxtecan shrank tumours in about 37 percent of patients overall and 61 percent of those with the highest HER2 expression, leading to a tumour-agnostic approval.

Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.

Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.

A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.

A cancer with too much HER2 growth-signal protein, either scored 3+ on the stain or shown to have extra copies of the gene. Once the most aggressive breast cancer subtype, it is now among the most treatable thanks to anti-HER2 drugs.

Jazz Pharmaceuticals, based in Dublin, sells zanidatamab (Ziihera), a HER2-targeting antibody, outside Asia for biliary tract and gastro-oesophageal cancer, alongside Rylaze, Zepzelca (lurbinectedin) and CPX-351 for acute myeloid leukaemia. Whether zanidatamab can grow from a rare bile duct indication into gastric cancer is its open question.

Between one in eleven and one in five gallbladder cancers is HER2-positive and two HER2 drugs are now approved, but testing still happens only when someone asks. Making it automatic on every advanced biliary diagnosis, on resection tissue where it exists, would find the patients the trials were built for.

Removing a gallbladder that contains stones before it causes trouble, in the hope of preventing a cancer that almost always arises in a gallbladder with stones. Chile has run a national programme since 2006.

Chile has guaranteed gallbladder removal for people aged 35 to 49 with gallstones since 2006 to prevent gallbladder cancer; this review of official data finds deaths falling but already falling before the programme, and uptake not matching the regions where the cancer is commonest.

In the first years of Chile's preventive gallbladder surgery guarantee, deaths from gallbladder cancer among 35 to 49 year olds fell twice as fast as before, but the national trend did not visibly change.

An epidemiological analysis, with US National Cancer Institute authors, of whether Chile's preventive gallbladder surgery programme has cut deaths from gallbladder cancer.

India carries about a tenth of the world's gallbladder cancer, concentrated in the north and east, striking younger people than in the West, with gallstones present in four out of five patients and a list of environmental co-factors under suspicion.

Of nearly 2,000 people with gallbladder cancer seen at Mumbai's Tata Memorial in four years, six in ten already had spread when they arrived and only one in six could be offered treatment aimed at cure.

Pooling more than a thousand cases, people with signs of past or chronic typhoid infection were four to five times more likely to have gallbladder cancer, though the bacterium itself was not recovered from the Chilean patients studied.

Across 17 studies, mostly from India and China, people who carried the typhoid bacterium long term were about four times as likely to have gallbladder cancer, and the authors suggest offering them gallbladder removal or ultrasound checks.

The 2022 European rules for gallbladder polyps found on ultrasound: operate at 10 mm or more, operate at 6 to 9 mm if there are risk factors, scan again for two years otherwise, and stop watching tiny polyps in people without risk factors.

Following more than 600,000 people for two decades, those with gallbladder polyps on ultrasound were no more likely to get gallbladder cancer than those without, though the risk did climb for polyps of a centimetre or more; the authors question whether watching polyps finds cancer at all.

A small growth on the inside wall of the gallbladder, usually spotted by chance on an ultrasound scan. Most are harmless cholesterol deposits; the risk of cancer rises with size, so polyps of 10 mm or more are removed with the gallbladder and smaller ones are watched or left alone according to set rules.

India's largest cancer centre, a leader in low-cost, high-impact trials such as low-dose immunotherapy and oral metronomic chemotherapy.

Stopping cancer from starting: vaccines, germline testing, lifestyle, and preventive drugs or surgery.

In parts of Chile and northern India gallbladder cancer is common enough that a cheap ultrasound programme aimed at the highest-risk people might catch it while surgery can still cure it. Nobody has run the trial.

Chile has paid for preventive gallbladder removal in 35 to 49 year olds with stones since 2006 without a design that can show whether it prevents cancer deaths. Targeting the operation by region, ancestry and risk score, with an evaluation built in, would answer the question the world's only such programme has left open for twenty years.

People who carry the typhoid bacterium in their gallbladder long term have about four times the usual risk of gallbladder cancer. Two meta-analyses suggest offering them gallbladder removal or regular scans; no programme has tried it.

A US trial asking whether people whose gallbladder cancer was found by chance should have chemotherapy before their second operation rather than only after it.

A German phase 3 of chemotherapy before the second operation for incidental gallbladder cancer that closed in October 2024 with 68 of a planned 333 participants; its report will show how much a small trial can say.

An Indian randomised trial asking whether adding radiotherapy to chemotherapy before surgery shrinks locally advanced gallbladder cancer enough to help people live longer.

The large European trial that will say whether the two-drug chemotherapy used for advanced disease beats capecitabine tablets as the treatment after surgery for bile duct and gallbladder cancer.

A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.

Tests whether the HER2 bispecific antibody should be given from the start in HER2-positive bile duct cancer.

In 167 people whose bile duct or gallbladder cancer had been removed, a blood test for tumour DNA in the weeks after surgery picked out those whose cancer would return far better than the standard blood markers.

In 56 people after surgery for bile duct or gallbladder cancer, finding tumour DNA in the blood in the weeks after the operation meant the cancer came back within about seven months on average, while those without it had not relapsed by the end of follow-up.

An ultra-sensitive blood test after surgery that detects leftover cancer months before a scan would.

A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.

After surgery for bile duct or gallbladder cancer, a blood test for leftover tumour DNA picks out the people whose cancer will return with hazard ratios of 16 to 26 in two recent cohorts. Nobody has yet tested giving those people more than the standard capecitabine.

Gallbladder cancers found by chance often come back within six months of the second operation, usually far from the gallbladder, which suggests the disease was already in the bloodstream. Two randomised trials are testing chemotherapy first; one closed small, the other reports in 2028.

A 2004 review arguing that gallbladder cancer, rare and little studied, is worth understanding because its mix of inherited risk, geography, female predominance, chronic inflammation and congenital anomalies is unusual among cancers.

The 2022 Nature Reviews primer on gallbladder cancer: the commonest biliary cancer, mostly found by chance at gallstone surgery, driven by long-standing inflammation, curable only by surgery and badly in need of screening biomarkers and separate study.

Sequencing 262 gallbladder tumours from Chile, China, India, Japan and South Korea showed that the mutations differ by country and ancestry, with Chinese tumours carrying the most mutations and Chilean the fewest.

Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.

Research money follows visibility, not burden: breast, prostate and leukaemia receive far more funding per death or year of life lost than lung, pancreatic, liver, oesophageal, gastric, bladder and uterine cancers, and metastasis research gets an estimated 5% of funding despite causing most deaths. Advocacy strength and peer review that rewards mechanism explain the skew.

Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.

Gallbladder cancer has been called scantily understood in 2004 and understudied in 2025 by its own researchers. Counting the money spent on it against the deaths it causes, country by country, would make the gap visible and give funders a target.

Every drug gallbladder cancer patients receive was tested in mixed bile duct trials where they were a subgroup. Requiring trials to pre-specify and publish gallbladder results, with a minimum number enrolled, would give the disease its own evidence at almost no cost.

About six in every thousand gallbladders removed for stones contain cancer. A written pathway that sends every specimen to the pathologist, refers every T1b or deeper cancer to a liver surgeon within two weeks and books the second operation within eight would turn a lottery into a system.